Vericel Corp VCEL
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $47.52
- Day Range
- $45.98–47.94
- 52-Week Range
- $29.24–53.05
- Bid/Ask
- $46.25 / $56.53
- Market Cap
- $2.24 Bil
- Volume/Avg
- 319,426 / 456,353
Key Statistics
- Price/Earnings (Normalized)
- 101.84
- Price/Sales
- 11.45
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company, specialized in various therapies for sports medicine and severe burn care markets. It markets two cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane) and Epicel (cultured epidermal autografts). The company operates in one reportable segment: the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 314
- Website
- https://www.vcel.com
Comparables
Valuation
|
Metric
|
VCEL
|
LYEL
|
PTGX
|
|---|---|---|---|
Price/Earnings (Normalized) | 101.84 | — | — |
Price/Book Value | 10.06 | 0.93 | 4.48 |
Price/Sales | 11.45 | 4,652.51 | 24.70 |
Price/Cash Flow | 57.58 | — | — |
Price/Earnings
VCEL
LYEL
PTGX
Financial Strength
|
Metric
|
VCEL
|
LYEL
|
PTGX
|
|---|---|---|---|
Quick Ratio | 3.67 | 15.82 | 16.54 |
Current Ratio | 4.49 | 16.07 | 16.71 |
Interest Coverage | −10.67 | — | — |
Quick Ratio
VCEL
LYEL
PTGX
Profitability
|
Metric
|
VCEL
|
LYEL
|
PTGX
|
|---|---|---|---|
Return on Assets (Normalized) | 7.35% | −20.62% | −16.60% |
Return on Equity (Normalized) | 11.01% | −23.35% | −18.20% |
Return on Invested Capital (Normalized) | 7.01% | −24.46% | −23.45% |
Return on Assets
VCEL
LYEL
PTGX
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Vnxqshvpfx | Vszpf | $551.2 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Mpgvjby | Pxdvym | $101.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Cnqljxd | Lvvqnb | $98.9 Bil | |
MRNA
| Moderna Inc | Svvwxdvt | Wvj | $39.7 Bil | |
ARGX
| argenx SE ADR | Swdnjjl | Pgqqy | $22.1 Bil | |
BNTX
| BioNTech SE ADR | Ttcbsbvh | Ptdvd | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Vsqlvclrk | Rncdys | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Wskczgf | Rmcnpy | $17.2 Bil | |
RPRX
| Royalty Pharma PLC Class A | Ccrqnbkcv | Zjwxkl | $12.3 Bil | |
INCY
| Incyte Corp | Mzrrkxrxv | Rdwmc | $11.8 Bil |